To include your compound in the COVID-19 Resource Center, submit it here.

TB-402: Phase IIb started

ThromboGenics and BioInvent began a double-blind, European Phase IIb trial to

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE